Molecular subtypes and precision treatment of triple-negative breast cancer

Area of Science:

• Oncology
• Genomics
• Molecular Biology

Background:

• Triple-negative breast cancer (TNBC) is the most aggressive subtype, with chemotherapy as the primary treatment.
• Targeted therapies for TNBC are limited, despite advances in precision medicine for other cancers.
• Inter-tumoral heterogeneity in TNBC necessitates novel classification strategies.

Purpose of the Study:

• To review current knowledge on TNBC molecular classification.
• To explore how molecular subtypes can guide precision treatment development.
• To discuss the future clinical application of molecular classification in TNBC.

Main Methods:

• Genomic and transcriptomic analyses using next-generation sequencing.
• Review of existing literature on TNBC molecular subtypes.
• Analysis of genetic aberrations and expression signatures.

Main Results:

• TNBC exhibits significant inter-tumoral heterogeneity.
• Molecular classification efforts aim to define distinct TNBC subtypes.
• Identification of potential novel therapeutic targets based on molecular profiles.

Conclusions:

• Molecular classification is crucial for understanding TNBC heterogeneity.
• Developing precision treatments for TNBC requires robust molecular subtyping.
• Future clinical practice may integrate molecular classification for personalized TNBC therapy.